Three US Food and Drug Administration–approved therapies for chronic GVHD-Reference-Cited by-同舟云学术

Three US Food and Drug Administration–approved therapies for chronic GVHD

Published:2022-03-17 Issue:11 Volume:139 Page:1642-1645
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zeiser Robert¹^ORCID,Lee Stephanie J.²^ORCID

Affiliation:

1. Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany; and

2. Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA

Abstract

Abstract Chronic graft-versus-host disease (cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/139/11/1642/1881999/bloodbld2021014448c.pdf

Reference35 articles.

1. Current use of and trends in hematopoietic cell transplantation in the United States;D’Souza;Biol Blood Marrow Transplant.,2020

2. Pathophysiology of chronic graft-versus-host disease and therapeutic targets;Zeiser;N Engl J Med.,2017

3. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report;Jagasia;Biol Blood Marrow Transplant.,2015

4. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report;Lee;Biol Blood Marrow Transplant.,2015

5. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain;Mohamed;Immunol Rev.,2009

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD;Cells;2024-09-11

2. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

3. Understanding Ocular Graft-Versus-Host Disease to Facilitate an Integrated Multidisciplinary Approach;Transplantation and Cellular Therapy;2024-07

4. Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation;Blood Advances;2024-05-17

5. Study protocol: Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH);PLOS ONE;2024-05-16